Abstract: The present invention relates to a bio-functionalized fibrous structure with a core/shell architecture for partial or total repair of human tendons or ligaments. The architecture based on a core/shell system grants to the fibrous structure a specific physical and mechanical behaviour when it is repeatedly mechanically loaded, as happens with a native tendon or ligament in constant usage in the human body. The core is based on several sub-components, namely braided structures parallelly assembled, which are enclosed by a braided shell. Additionally, a selective bio-functionalization of the two parts of the core/shell structure can be applied in order to selectively improve or avoid the in vivo cell adhesion.

Abstract: Oral care compositions comprising a capsules comprising flavoring and/or one or more active ingredients, and/or flavours, said capsules distributed in an orally acceptable vehicle or carrier.

Abstract: The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophage F387/08, F391/08, F394/08, F488/08, F510/08, F44/10, and F125/10, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophage and/or isolated polypeptides, as well as to methods for the treatment and prevention of bacterial infections using same, either alone or in combination with other antibacterial therapies, e.g., antibiotics and/or other phage therapies.

Abstract: The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.

Abstract: The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophage F387/08, F391/08, F394/08, F488/08, F510/08, F44/10, and F125/10, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophage and/or isolated polypeptides, as well as to methods for the treatment and prevention of bacterial infections using same, either alone or in combination with other antibacterial therapies, e.g., antibiotics and/or other phage therapies.

Abstract: The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophage F387/08, F391/08, F394/08, F488/08, F510/08, F44/10, and F125/10, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophage and/or isolated polypeptides, as well as to methods for the treatment and prevention of bacterial infections using same, either alone or in combination with other antibacterial therapies, e.g., antibiotics and/or other phage therapies.

Abstract: The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophage F387/08, F391/08, F394/08, F488/08, F510/08, F44/10, and F125/10, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophage and/or isolated polypeptides, as well as to methods for the treatment and prevention of bacterial infections using same, either alone or in combination with other antibacterial therapies, e.g., antibiotics and/or other phage therapies.

Abstract: The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.

Abstract: The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophage F387/08, F391/08, F394/08, F488/08, F510/08, F44/10, and F125/10, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophage and/or isolated polypeptides, as well as to methods for the treatment and prevention of bacterial infections using same, either alone or in combination with other antibacterial therapies, e.g., antibiotics and/or other phage therapies.

Abstract: The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.

Abstract: The disclosed invention refers to a process for obtaining fatty acid alkyl esters, rosin acids and sterols from crude tall oil (CTO), which is characterized by the following steps: (a) reacting the free fatty acids present in the CTO with lower alcohols; (b) esterifying the sterols in the CTO with boric acid or transesterifying the sterols with a catalyst; (c) separating the fatty acid lower alkyl esters and rosin acids from the remaining sterol borate esters or sterol esters of fatty acids to produce a stream of sterol esters; (d) separating the fatty acid alkyl esters from the rosin acids to produce a first stream of fatty acid alky esters and a second stream of rosin acids; and (e) converting the sterol esters into the free sterols to produce a third stream of free sterols.

Abstract: The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophage F387/08, F391/08, F394/08, F488/08, F510/08, F44/10, and F125/10, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophage and/or isolated polypeptides, as well as to methods for the treatment and prevention of bacterial infections using same, either alone or in combination with other antibacterial therapies, e.g., antibiotics and/or other phage therapies.

Abstract: The present invention is directed to isolated and chimeric polypeptides of bacteriophage origin having antibiotic activity and use thereof in the treatment and control of bacterial infections. Specifically, the present invention is directed to the use of a novel antibacterial polypeptide derived from bacteriophage F87s/06 and chimeric constructs thereof, and their use for the treatment and control of infections caused by gram-positive bacteria, including Staphylococcus aureus.

Abstract: Oral care compositions comprising a capsules comprising flavoring and/or one or more active ingredients, and/or flavours, said capsules distributed in an orally acceptable vehicle or carrier.

Abstract: The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.

Abstract: The present invention is directed to isolated and chimeric polypeptides of bacteriophage origin having antibiotic activity and use thereof in the treatment and control of bacterial infections. Specifically, the present invention is directed to the use of a novel antibacterial polypeptide derived from bacteriophage F87s/06 and chimeric constructs thereof, and their use for the treatment and control of infections caused by gram-positive bacteria, including Staphylococcus aureus.

Abstract: The invention relates to plasticizer compositions for polyvinyl chloride resins. A plasticized polyvinyl chloride resin contains (a) 100 parts by weight of at least one polyvinyl chloride resin and (b) 0.1 to 200 parts by weight of a plasticizer compounded with the polyvinyl chloride resin, wherein the plasticizer comprises (i) at least one isobutanol ester of a fatty acid with 8 to 24 carbon atoms, wherein, the fatty acid can be saturated or olefinically unsaturated, linear or branched and contain at least one epoxy group per molecule and (ii) at least one methyl ester of a fatty acid with 16 to 18 carbon atoms, wherein, the fatty acid can be saturated or olefinically unsaturated, linear or branched.

Abstract: An RF tag has an enable/disable circuit connected to a critical part of an electronic object/circuit, e.g. a computer mother board. The critical part of the circuit is any circuit component and/or connection that can enable and/or disable the electric circuit operation. Signals are sent to the tag to change data in the tag memory which causes the enable/disable tag circuit to control the critical part to enable and disable the electric circuit. A system checks the status of the tag, e.g. the electronic circuit was paid for, before enabling the electronic circuit.

Abstract: A method of selecting groups of radio frequency RF transponders (tags) for communication between a base station and the tags. The tags are selected into groups according to a physical attribute of the signal sent by the tags to the base station, or according to the physical response of the tags to a physical attribute of the signal sent from the base station to the tags. Communication with the tags is thereby simplified, and the time taken to communicate with the first tag is markedly reduced.

Abstract: An RF tag has an enable/disable circuit connected to a critical part of an electronic object/circuit, e.g. a computer mother board. The critical part of the circuit is any circuit component and/or connection that can enable and/or disable the electric circuit operation. Signals are sent to the tag to change data in the tag memory which causes the enable/disable tag circuit to control the critical part to enable and disable the electric circuit. A system checks the status of the tag, e.g. the electronic circuit was paid for, before enabling the electronic circuit.